Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 9, 2012

View Archived Issues

AstraZeneca highlights key events of fourth quarter and FY2011

Japanese study compares drugs to retard symptom progression after stroke

Carbon nanomaterials display antioxidant characteristics

Pfizer prepares new voltage-gated K(V)7.2 and K(V)7.3 potassium channel openers

New melanin-concentrating hormone MCH1 receptor modulators disclosed

Mitsubishi Tanabe Pharma recaps recent highlights

Recordati presents new metabotropic glutamate mGlu5 receptor antagonists

Novel vaccine against C. perfringens patented in India

New compounds extracted from Cymbidium disclosed by Kawano Mericlone

Cormus designs novel lipid-conjugated antibodies

Significant benefit seen with adalimumab in ulcerative colitis

Detailed results presented of phase III regorafenib study

Forest Laboratories and Gedeon Richter report phase III cariprazine data

Milestones achieved in Pepscan Therapeutics/Janssen R&D Ireland collaboration

RedHill receives approval from Health Canada to begin RHB-102 trial

GSK launches over-the-counter cold sore product in Europe

ImmunoCellular Therapeutics provides pipeline update

New stem cell therapy improves stroke outcome in preclinical models

Cytomedix completes acquisition

Wellcome Trust launches new scheme to fund early-stage research in orphan and neglected diseases

Prometheus Laboratories enters collaboration with leading pharmaceutical company

Moberg Derma analyzes phase II data on nail fungus therapy

Ironwood Pharmaceuticals gives update on linaclotide NDA

MRF to assess ENDECE Neural's myelin regenerative compounds for MS

Siemens enters partnerships with ViiV Healthcare and Tocagen

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...